Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813643 | 0.84 | KDM1A (0.38) | CA1CA2MAPTKDM4EL3MBTL1 | |
| SCHEMBL1857409 | 0.71 | CA2 (0.36) | NOTUMCA1CA2F11MAPT | |
| SCHEMBL28202180 | 0.67 | TSHR (0.40) | MAPTKDM4ETSHRALDH1A1MAOA | |
| SCHEMBL24621213 | 0.67 | AKR1B1 (0.50) | MAPTKDM4EGAAL3MBTL1MMP2 | |
| SCHEMBL28582333 | 0.65 | PARP15 (0.37) | NOTUMCA1CA2CA12CA9 | |
| SCHEMBL9651804 | 0.65 | NOTUM (0.36) | NOTUMCA1CA2MAPTTSHR | |
| SCHEMBL7041642 | 0.65 | — | — | |
| SCHEMBL5959219 | 0.64 | NPSR1 (0.43) | NOTUMMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL27367482 | 0.64 | TSHR (0.39) | CA2KDM4ETSHRALDH1A1CA12 | |
| SCHEMBL1907012 | 0.63 | DDAH1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450811-B1 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARM INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| EP-2050751-A1 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-2011499-A2 | Pyrrolo[2,3d]Pyrimidine compositions and their use | OSI Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002057267-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1082120-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI Pharmaceuticals, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999062518-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | NOTUM 4828/4885CA1 4521/4885CA2 3843/4885 |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | NOTUM 4401/4885CA1 3157/4885CA2 2481/4885 |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | NOTUM 4401/4885CA1 3157/4885CA2 2481/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | NOTUM 4531/4885CA1 4534/4885CA2 3494/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | NOTUM 4312/4885CA1 2950/4885CA2 2551/4885 |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | NOTUM 4790/4885CA1 4749/4885CA2 4520/4885 |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | ADORA2A, ADORA2B, ADORA3 | NOTUM 4611/4885CA1 3189/4885CA2 1949/4885 |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | NOTUM 4475/4885CA1 3775/4885CA2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.